Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD-(L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer. The US regulator ...

Guidance in the UK has cleared the way for NHS use of digital health technologies (DHTs) that can support people with osteoarthritis and the eating disorder bulimia. The two new early value assessment ...

Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate "safe and helpful answers" to questions posed by healthcare professionals and ...

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price ...

An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public.

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was formed to produce improved, more potent shots that are simpler to manufacture.

NHS waiting lists are like fires that everyone in health is frantically trying to put out. But however much water we pour on it, the flames keep roaring. Waiting list numbers rose again in September, ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially ...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden's ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...